Please upgrade your browser.
David participated in a Phase 2 clinical study that evaluated a personalized cancer immunotherapy in combination with a standard targeted drug therapy, sunitinib.
Emails Tell the Story of the NCI Cancer Bulletin
SAN ANTONIO - Five years, local attorney Henry Grun had his will ready to be executed at the request of his first oncologist, who warned him that his kidney cancer was so aggressive he had only six months to live.
Astellas Pharma today announced that new clinical data on tivozanib, an investigational agent for the treatment of metastatic renal cell carcinoma (mRCC), will be presented at the 2013 American society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 14-16 in Orlando, Florida.
Cerulean Pharma Inc., a leader in designing and developing dynamically tumor-targeted nanopharmaceuticals, today announced that Scott D. Eliasof, Ph.D, vice president of research, will present data on Cerulean’s most advanced experimental cancer treatment, CRLX101, at the 15th International Symposium on Anti-angiogenic Therapy.
The exact incidence of carcinoma in horseshoe kidney has not been described in literature but the observation has been made that it is higher - approximately 3 to 4 times greater than that of the rest of the population.
Penn State freshman tight end Adam Breneman has been named an officer of Penn State's Uplifting Athletes chapter, the university announced.
These videos are sponsored by AVEO Oncology and Astellas Oncology.
Get the newest kidney cancer clinical trials app for the Apple iPad and iPhone
|Powered by NeonCRM|